vs
Side-by-side financial comparison of BayCom Corp (BCML) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $25.9M, roughly 1.5× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -161.8%, a 188.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-71.3M).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
BCML vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $38.3M |
| Net Profit | $6.9M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 36.6% | -169.0% |
| Net Margin | 26.5% | -161.8% |
| Revenue YoY | 9.4% | 407.0% |
| Net Profit YoY | 12.1% | -4.7% |
| EPS (diluted) | $0.63 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $38.3M | ||
| Q3 25 | $25.7M | $32.1M | ||
| Q2 25 | $24.7M | $26.4M | ||
| Q1 25 | $24.3M | $16.5M | ||
| Q4 24 | $23.7M | $7.6M | ||
| Q3 24 | $25.6M | $6.1M | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $24.5M | — |
| Q4 25 | $6.9M | $-61.9M | ||
| Q3 25 | $5.0M | $-67.3M | ||
| Q2 25 | $6.4M | $-92.6M | ||
| Q1 25 | $5.7M | $-129.6M | ||
| Q4 24 | $6.1M | $-59.2M | ||
| Q3 24 | $6.0M | $-85.7M | ||
| Q2 24 | $5.6M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 36.6% | -169.0% | ||
| Q3 25 | 26.3% | -173.5% | ||
| Q2 25 | 35.3% | -269.8% | ||
| Q1 25 | 31.6% | -390.1% | ||
| Q4 24 | 34.2% | -919.0% | ||
| Q3 24 | 32.4% | -1314.3% | ||
| Q2 24 | 31.9% | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | 26.5% | -161.8% | ||
| Q3 25 | 19.5% | -209.8% | ||
| Q2 25 | 25.8% | -350.3% | ||
| Q1 25 | 23.4% | -784.9% | ||
| Q4 24 | 25.9% | -783.4% | ||
| Q3 24 | 23.5% | -1404.0% | ||
| Q2 24 | 23.6% | — | ||
| Q1 24 | 24.0% | — |
| Q4 25 | $0.63 | $-0.06 | ||
| Q3 25 | $0.46 | $-0.07 | ||
| Q2 25 | $0.58 | $-0.10 | ||
| Q1 25 | $0.51 | $-0.15 | ||
| Q4 24 | $0.55 | $-0.08 | ||
| Q3 24 | $0.54 | $-0.14 | ||
| Q2 24 | $0.50 | — | ||
| Q1 24 | $0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $-500.5M |
| Total Assets | $2.6B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | — | $257.8M | ||
| Q2 25 | — | $153.7M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $338.6M | $-500.5M | ||
| Q3 25 | $334.3M | $-524.3M | ||
| Q2 25 | $330.6M | $-570.7M | ||
| Q1 25 | $329.3M | $-591.4M | ||
| Q4 24 | $324.4M | $-489.1M | ||
| Q3 24 | $321.7M | $-745.1M | ||
| Q2 24 | $315.3M | — | ||
| Q1 24 | $314.2M | — |
| Q4 25 | $2.6B | $501.9M | ||
| Q3 25 | $2.6B | $519.0M | ||
| Q2 25 | $2.6B | $402.1M | ||
| Q1 25 | $2.6B | $303.8M | ||
| Q4 24 | $2.7B | $382.9M | ||
| Q3 24 | $2.6B | $364.6M | ||
| Q2 24 | $2.6B | — | ||
| Q1 24 | $2.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-70.4M |
| Free Cash FlowOCF − Capex | $30.1M | $-71.3M |
| FCF MarginFCF / Revenue | 116.2% | -186.2% |
| Capex IntensityCapex / Revenue | 6.7% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-70.4M | ||
| Q3 25 | $7.3M | $-68.9M | ||
| Q2 25 | $6.4M | $-79.7M | ||
| Q1 25 | $9.3M | $-85.9M | ||
| Q4 24 | $30.4M | $-85.1M | ||
| Q3 24 | $9.6M | $-98.8M | ||
| Q2 24 | $7.7M | — | ||
| Q1 24 | $5.1M | — |
| Q4 25 | $30.1M | $-71.3M | ||
| Q3 25 | $6.2M | $-69.6M | ||
| Q2 25 | $5.6M | $-80.8M | ||
| Q1 25 | $9.1M | $-87.0M | ||
| Q4 24 | $28.7M | $-87.3M | ||
| Q3 24 | $9.4M | $-101.6M | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | 116.2% | -186.2% | ||
| Q3 25 | 24.3% | -217.2% | ||
| Q2 25 | 22.8% | -305.9% | ||
| Q1 25 | 37.6% | -526.9% | ||
| Q4 24 | 121.1% | -1155.4% | ||
| Q3 24 | 36.6% | -1663.2% | ||
| Q2 24 | 31.2% | — | ||
| Q1 24 | 16.1% | — |
| Q4 25 | 6.7% | 2.4% | ||
| Q3 25 | 4.3% | 2.3% | ||
| Q2 25 | 3.0% | 4.1% | ||
| Q1 25 | 0.6% | 6.8% | ||
| Q4 24 | 7.2% | 28.0% | ||
| Q3 24 | 1.0% | 45.7% | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 4.7% | — |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
